Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QRFPR | Q96P65 | 8/20 | 0.57 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.48 |
| ▸ | GNPAT | O15228 | 1/20 | 0.48 |
| ▸ | NPY4R | P50391 | 1/20 | 0.46 |
| ▸ | NPY1R | P25929 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.42 |
| ▸ | CHRNG | P07510 | 1/20 | 0.42 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.42 |
| ▸ | CHRND | Q07001 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24191597 | 0.86 | QRFPR (0.54) | QRFPRC3AR1GNPATPTGER4 | |
| SCHEMBL29590419 | 0.85 | QRFPR (0.60) | QRFPRGNPATNPY4RNPY1ROPRM1 | |
| Trifluoroacetic Acid SCHEMBL23630169 | 0.84 | LTA4H (0.53) | QRFPRGNPAT | |
| Trifluoroacetic Acid SCHEMBL23630172 | 0.84 | LTA4H (0.53) | QRFPRGNPAT | |
| SCHEMBL29865306 | 0.83 | KISS1R (0.53) | QRFPRC3AR1GNPATNPY4RNPY1R | |
| SCHEMBL31075598 | 0.83 | REN (0.50) | QRFPRC3AR1GNPATOPRM1OPRD1 | |
| SCHEMBL30051999 | 0.82 | CTSB (0.55) | QRFPRGNPATOPRM1OPRD1OPRK1 | |
| SCHEMBL23142822 | 0.82 | CTSB (0.55) | QRFPRGNPATOPRM1OPRD1OPRK1 | |
| SCHEMBL23142823 | 0.82 | CTSB (0.55) | QRFPRGNPATOPRM1OPRD1OPRK1 | |
| SCHEMBL30051480 | 0.82 | CTSB (0.55) | QRFPRGNPATOPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-07-29 | — | — | US | disclosed |
| EP-4524154-A2 | ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2025-03-19 | — | — | EP | disclosed |
| EP-3848054-B1 | ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2025-01-29 | — | — | EP | disclosed |
| US-20240293567-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-09-05 | — | — | US | disclosed |
| US-20220008549-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-01-13 | — | — | US | disclosed |
| EP-3848054-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | Daiichi Sankyo Company, Limited (JP) | 2021-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | STING1, CGAS, CDA | QRFPR 984/4885C3AR1 201/4885GNPAT 2132/4885 |
| US-20220008549-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | STING1, CGAS, TLR9 | QRFPR 900/4885C3AR1 143/4885GNPAT 2346/4885 |
| US-20240293567-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | STING1, CGAS, TLR9 | QRFPR 900/4885C3AR1 143/4885GNPAT 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.